4P-003

4P-003 is a preclinical-stage drug candidate being developed by 4P-Pharma for the treatment of stimulant use disorders (SUD), including addiction to cocaine and methamphetamines. The program utilizes a drug repositioning strategy, which involves identifying new therapeutic applications for existing, off-patent compounds to accelerate development timelines. While the specific chemical identity and molecular targets of 4P-003 remain proprietary, the asset is designed to address the significant unmet medical need in addiction medicine, where no FDA-approved pharmacotherapies currently exist for stimulant-specific use disorders. As of recent pipeline updates, the project is in the lead optimization and preclinical evaluation phase.